Overview

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Ofatumumab
Vidarabine